A Cost-Effective De-escalation Strategy in Advanced Melanoma

Response-adapted de-escalation of ipilimumab in patients with advanced melanoma has the potential to lower healthcare costs.
Medscape Medical News

source https://www.medscape.com/viewarticle/983269?src=rss